Examkin

Question

Difficulty: MediumDepressive Disorders

A 34-year-old graphic designer comes to the office for a follow-up visit. Four weeks ago, she presented with pervasive sadness, hypersomnia, increased appetite, and a heavy feeling in her limbs. She was diagnosed with a major depressive episode and started on sertraline 50 mg daily. Today, she reports that her mood has not improved and she is frustrated. She says, "I stopped taking the pill three days ago because it wasn't working fast enough. Can we just try something else?" Upon further questioning, the patient mentions that three years ago, she experienced a 10-day period where she felt "incredibly energized," required only 2 hours of sleep per night without feeling tired, and impulsively drained her savings account to start a speculative business venture that quickly failed. She has no history of hallucinations or delusions. Physical examination is unremarkable. Which of the following is the most appropriate next step in management?

  1. Initiate therapy with an atypical antipsychotic such as quetiapineAnswer
  2. B
    Reassure the patient that antidepressants take 4 to 6 weeks for full effect and resume sertraline
  3. C
    Switch from sertraline to bupropion monotherapy
  4. D
    Add phenelzine to her regimen to rapidly augment the antidepressant effect
  5. E
    Diagnose schizophreniform disorder and begin treatment with haloperidol

Answer

Initiate therapy with an atypical antipsychotic such as quetiapine.
The correct answer recognizes that this patient has Bipolar I Disorder, currently in a depressive episode. Her history of a 10-day period of extreme energy, decreased need for sleep, and severe impulsivity meets the diagnostic criteria for a manic episode. In the treatment of bipolar depression, antidepressant monotherapy (such as resuming sertraline or switching to bupropion) is generally contraindicated because it can precipitate a manic switch and is frequently ineffective. First-line treatments for acute bipolar depression include specific atypical antipsychotics (e.g., quetiapine, lurasidone, cariprazine) or mood stabilizers (e.g., lithium, lamotrigine). Therefore, initiating quetiapine is the most appropriate next step in her management.

Step-by-Step Solution

1
Analyze the patient's past psychiatric history.
The patient describes a 10-day period of severe elevated energy, decreased need for sleep, and impulsive financial behavior.
These symptoms meet the DSM-5 criteria for a manic episode (lasting at least 7 days), which changes the primary diagnosis from Major Depressive Disorder (MDD) to Bipolar I Disorder.
2
Evaluate the current presentation in the context of the new diagnosis.
The patient is currently experiencing a bipolar depressive episode with atypical features (hypersomnia, hyperphagia, leaden paralysis).
Treatment guidelines for bipolar depression differ significantly from unipolar depression.
3
Identify the contraindications in the current or proposed pharmacological plan.
Resuming sertraline or switching to another antidepressant monotherapy (like bupropion) is contraindicated due to the risk of precipitating a manic switch. Adding an MAOI is contraindicated due to the lack of a 14-day washout period.
Bipolar depression requires mood stabilizers or specific atypical antipsychotics, and combining serotonergic drugs inappropriately risks Serotonin Syndrome.
4
Select the most appropriate evidence-based therapy.
Initiating quetiapine is correct.
Quetiapine (along with lurasidone, lithium, and lamotrigine) is an established first-line treatment for acute bipolar depression.

Key Concept

Patients presenting with depressive episodes must be carefully screened for a lifetime history of mania or hypomania. If a history of mania is present, the diagnosis is Bipolar I Disorder, and antidepressant monotherapy is generally contraindicated due to the risk of inducing a manic switch.
Rate this question

Topics

Depressive Disorders

More questions from this topic